Oxford BioTherapeutics Wins Rights to Amgen Antibodies, ImmunoGen ADC ... Genetic Engineering News Oxford BioTherapeutics said today it obtained exclusive global rights to some of Amgen's Xenomouse® antibodies and ImmunoGen's maytansinoid antibody-drug conjugate (ADC) technology, with plans to develop a new ADC targeting an undisclosed ... Oxford BioTherapeutics Takes Exclusive Rights to Use Amgen Xenomouse ... |
